Sarepta Therapeutics has faced a second patient death from acute liver failure linked to its Duchenne muscular dystrophy gene therapy, Elevidys. Both fatalities involved non-ambulatory patients. The company has suspended shipments for this subgroup while evaluating an enhanced immunosuppressive regimen intended to mitigate liver toxicity risks. Sarepta is assembling an independent expert panel to guide this effort and will coordinate with regulatory bodies before resuming treatment under updated safety protocols. The developments have caused concern within the DMD community and stirred questions over FDA's forthcoming regulatory response.